44 filings
8-K
SLRN
Acelyrin Inc
11 Jun 24
Submission of Matters to a Vote of Security Holders
5:05pm
8-K/A
SLRN
Acelyrin Inc
28 May 24
Departure of Directors or Certain Officers
5:20pm
10-Q
2024 Q1
SLRN
Acelyrin Inc
Quarterly report
14 May 24
4:22pm
DEFA14A
SLRN
Acelyrin Inc
9 May 24
Additional proxy soliciting materials
8:14am
8-K
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
ARS
7p1h2eumw2ngusxtd4
22 Apr 24
Annual report to shareholders
4:19pm
DEFA14A
y0938clvd1qo
22 Apr 24
Additional proxy soliciting materials
4:14pm
DEF 14A
rit6bm
22 Apr 24
Definitive proxy
4:10pm
S-8
jwu6v1
28 Mar 24
Registration of securities for employees
4:43pm
10-K
ewipj6y lgiz4
28 Mar 24
Annual report
4:21pm
8-K
noz1ovwev ttk3eidd
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
lc1sy
20 Mar 24
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile
7:04am
8-K
7t6ah e3eu
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
c1k 3dja1
20 Dec 23
Departure of Directors or Certain Officers
4:38pm
8-K
tyzhr5sak3foyd
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
htqi00qlq c5sb5
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
hwm7c8
21 Aug 23
Departure of Directors or Certain Officers
4:03pm
8-K
v8hkkx410elhhhlsipb
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm